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NICE and Society 
Health technology appraisal and the cultivation of social relations 
Matthias Benzer 
 
Abstract: This article presents a sociological inquiry into the politics of the UK National 
,QVWLWXWHIRU+HDOWKDQG&DUH([FHOOHQFH·VDSSURDFKWRKHDOWKWHFKQRORJ\DSSUDLVDOVIt is based 
on analyses of documents published by NICE and of a 2005-2008 interdisciplinary debate about 
the ethics of its activities. Simultaneously, the article brings further perspectives to this debate by 
clarifying that NICE, through the comparisons central to its approach, arranges a competition in 
producing health between different treatments applied to their respective particular patient 
groups. In fosteULQJFRPSHWLWLRQIRUGLIIHUHQWLDWLRQ1,&(·VDSSURDFKUHVHPEOHVREMHFWLYHVIRU
shaping social relationships often attributed to neoliberal politics. Yet closer scrutiny reveals that 
1,&(·V FUHDWLRQ RI SRVLWLRQV IRU DQG UHODWLRQV EHWZHHQ SDWLHQWV LV VLPXOtaneously more 
problematic. A FRPSDULVRQEHWZHHQ1,&(·VZRUNDQGORQJVWDQGLQJVRFLRORJLFDOFRQFHSWLRQVRI
the social relationship offers insight into WKH TXDOLW\ RI WKH VRFLDO UHODWLRQV 1,&(·V DSSURDFK
supports in more general terms. 
 
Keywords: National Institute for Health and Care Excellence, comparison, competition, 
neoliberalism, social relations 
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 Introduction 
 The National Institute for Health and Care Excellence (NICE) in the British National 
+HDOWK6HUYLFH 1+6 LV WDVNHGZLWKSURGXFLQJ´HYLGHQFH-based guidance on health and social 
FDUHµ (NICE, 2018). Its work programme comprises developing, inter alia, guidelines (for 
example, clinical and public health guidelines) (2019c), appraisals of health technologies (such as 
drugs, devices, or procedures), diagnostics guidance, and recommendations regarding highly 
specialised technologies (2019b). NICE guidance is aimed at the NHS, healthcare commissioners 
and providers, local authorities, and charities, among others (2018). NICE is currently a non-
GHSDUWPHQWDOSXEOLFERG\´DFFRXQWDEOHWR«WKH'HSDUWPHQWRI+HDOWKDQG6RFLDO&DUHµ(2019e). 
<HWLWV´SURGXFWVDUHGHYHORSHGLQGHSHQGHQWO\RIJRYHUQPHQWLQIOXHQFHµ 
1,&(·VKHDOWKWHFKQRORJ\DSSUDLVDOs confront a major problem in the UK health system. 
The British health service is tax-funded (NHS, nd). Its resources, NICE asserts, are limited 
(2008: 9, 2013: 28, 50, 90; see also Claxton and Culyer, 2007: 463; Harris, 2005a: 373; Quigley, 
2007: 466; Rawlins and Dillon, 2005: 683). A NH\ ´SURSRVLWLRQµ LQ 1,&(·V WKLQNLQJ LV WKDW
funding an LQWHUYHQWLRQ IRU RQH SDWLHQW JURXS FRPHV DW WKH SULFH RI ´KHDOWK EHQHILWVµ WKXV
unavoidably kept from others (Claxton and Culyer, 2006: 373). A conflict between different 
patient groups· demands on healthcare funding can be seen to arise. The situation is one of 
´OLPLWHGUHVRXUFHVDQGFRPSHWLQJKHDOWKFDUH LQWHUHVWVµ (Quigley, 2007: 466). NICE technology 
appraisals involve making recommendations regarding which procedures the NHS should and 
should not resource for patients (NICE, 2013: 66-67). NHS England and commissioning groups 
PXVW ´FRPSO\ZLWKµ DSSUDLVDO recommendations (2019b, see also 2019d). NHS ´patients have 
the right to drugs and treatmentV«recommended by NICE for use in the NHSµ, provided their 
doctor finds WKHP´FOLQLFDOO\DSSURSULDWHµ (2018). 
The limitation of healthcare resources poses the problem of how they ought to be 
allocated (Rawlins and Dillon, 2005: 683). NICE considers optimising population health from 
the fixed NHS budget one of its guiding objectives (2008: 9, 2013: 28, 31-32, 50, 65-66, 90; 
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Claxton and Culyer, 2008: 599, 601). Health means QALYs, quality-adjusted life years, lifetime 
weighted correspondingly to quality of life (2013: 32-33, 38-40, 89). A well-known essential 
FRPSRQHQWRI1,&(·V-55) mode of developing recommendations is the assessment of 
different treatments for patients with various conditions in view of their cost-effectiveness: of 
how much health ² how many QALYs ² per amount of health expenditure they yield. 
In 2005, when he was Chairman of NICE, Michael Rawlins described the question 
´+RZ DV D VRFLHW\ VKRXOG ZH VHW SULRULWLHV IRU WKH PHGLFLQHV ZH XVH"µ DV D FRQWHPSRUDU\
´SKDUPDFRSROLWLFDO SUREOHPµ   This paper contributes a sociological inquiry to the 
literature RQWKHSROLWLFVRI1,&(·VDFWLYLWLHV. It draws upon analyses of documents published by 
NICE and of interventions by critics and defenders of the Institute in a debate on the ethics of 
its work. As key components of NICE appraisal are thus clarified, the terms of that debate are 
simultaneously extended. On this basis, it is shown KRZ 1,&(·V DSSUDLVDO DSSURDFK fosters 
relations of competition for the purpose of differentiation. At the same time, though, its 
approach creates a position for the people involved in this competition that differs from what 
many sociologists regard as the position of agents of competition. Finally, the way in which 
1,&(·VDFWLYLWLHVVKDSHVRFLDOUHODWions between people is elucidated in more general sociological 
terms. 
 
 Technology appraisal under scrutiny 
This paper extends the sociological scholarship on technology appraisal in four domains. 
In studies of the politics of health technology assessment and related activities, the politics of 
evidence has been a persistent concern. 0D\·V VWXG\ RI UK telehealthcare development and 
evaluation documents doubts about evidence produced through approaches associated with 
health technology assessment, notably clinical trials. It reports NHS and social care managers·
calls for alternative modes of generating evidence (2006: 521-528). This, May argues, has 
LPSOLFDWLRQVIRUWKHQRWLRQVRIDQHPHUJLQJ´HYLGHQFH-EDVHGSROLF\µDQGRID´¶SRVW-LGHRORJLFDO·
4 
 
SROLWLFVµLQ*UHDW%ULWDLQ0LOHZDDQG%DUU\analyse the politics of evidence focusing 
RQ 1,&( 7KH\ KLJKOLJKW DQ RYHUDOO ´SULPDF\ RI DUJXPHQWV based on quantitatively oriented, 
H[SHULPHQWDOO\ GHULYHG GDWDµ LQ WKH ,QVWLWXWH·V DSSUDLVDO ´EXW DOVR«D GLVFXUVLYH KHJHPRQ\ RI
clinicians and health economists in mediating, including or debarring more qualitative, 
H[SHULHQWLDOO\ EDVHG HYLGHQFHµ  06). Milewa and Barry elucidate their findings with 
UHIHUHQFH WR´DGLVFXUVLYH DSSURSULDWLRQRI WKH ¶FRPPRQJRRG·µ   Investigating the 
politics of governance in turn, Milewa has observed that discussion in appraisal was affected by, 
inter alia, D ´SUHIHUHQFH IRU ¶H[SHUW MXGJHPHQW·µ DQG WKH YLHZ WKDW SDWLHQWV DQG FDUHUV ODFN
objectivity in evaluating interventions (2006: 3110, see also 3107-3108). These observations 
XQGHUVFRUHWKHLPSRUWDQFHRIGLVWLQJXLVKLQJ´GHPRFUDWLFGHOLEHUDWLRQµVXFKDVLQNICE, from 
´GHOLEHUDWLYH GHPRFUDF\µ   1RW RQO\ LQ Britain have such issues been framed in 
political terms, though. Lopes and colleagues (2015), for instance, GUDZRQ)RXFDXOW·VZRUN WR
scrutinise patient involvement in healthcare funding decisions in Australia. Patient 
UHSUHVHQWDWLYHVDQGPHPEHUVRIWKHFRPPLWWHHDGYLVLQJ$XVWUDOLD·V'HSDUWPHQWRI+HDOWKWKH\
report, disagree on what kinds of evidence should play a role (2015: 87-88). This reflects 
GLYHUJLQJ´HSLVWHPRORJLFDOVWDQGSRLQWVµ 90). Simultaneously, stakeholders forge alliances 
for submitting information and shaping policy more profoundly (2015: 88-90). Whilst these 
studies have generated important insights into the politics of evidence, governance, and 
involvement, one problem has largely escaped their focus, namely how appraisal shapes social 
relationships between patients. But this is a problem that has gravity beyond sociology, too. 
Notably, NICE itself has thematised, though by no means exhaustively examined, the potential 
of its work to affect relationships between people. 7KH  (TXDOLW\ $FW·V 3XEOLF 6HFWRU
(TXDOLW\'XW\1,&(KLJKOLJKWVIRULQVWDQFHGHPDQGVWKDW´LQFDUU\LQJRXWLWVIXQFWLRQV«µLW
´KDYH GXH UHJDUG WR WKH QHHG WR«IRVWHU JRRG UHODWLRQV LQ UHODWLRQ WR people who 
VKDUH«SURWHFWHGFKDUDFWHULVWLFVµ HJ UDFHRUGLVDELOLW\ 0RUHRYHU1,&(·V DFWLYLWLHV
KDYHIRUPDQ\\HDUVEHHQDVVLVWHGE\LWV&LWL]HQV&RXQFLO&RPSULVLQJ´WKLUW\PHPEHUVRIWKH
5 
 
%ULWLVKSXEOLFµ WKH&RXQFLO RIIHUV1,&(´DGYLFHRQ FKDOOHQJLQJ VRFLDO DQGPRUDO LVVXHVµ WKDW
DULVH ZKHQ ´JXLGDQFHµ LV being developed (2014: 1). The 2014 session·V DLPV LQFOXGHG, for 
example, ´WR UHFRUG«VSHFLILF LQVWDQFHV WKDW MXVWLI\ D PXFK JUHDWHU HPSKDVLV EHLQJ SODFHG RQ
DFKLHYLQJ HLWKHU HTXLW\ RU HIILFLHQF\µ  . In the following inquiry into the politics of 
1,&(·V KHDOWK WHFKQRORJ\ DSSUDLVDO DSSURDFK, the way in which it shapes social relations is 
examined in detail.  
Of note for this inquiry, previous investigations have raised the question of neoliberal 
politics. Crinson presents DFDVHVWXG\RI1,&(·VDSSUDLVDORIEHWDLQWHUIHURQDQGthe agreement 
of a risk-sharing scheme between the Department of Health and pharmaceutical companies 
(2004: 33- +H GHQLHV WKDW D ´SRVWPRGHUQLVW UHDGLQJ RI D VKLIW WRZDUGV D QHR-OLEHUDO ¶SRVW-
ZHOIDULVP·µFDQFDSWXUHWKHHDUO\VGHYHORSPHQWVLQWKH8.KHDOWKV\VWHP'HZ
and DaYLV·V analysis of WKH HVWDEOLVKPHQW DQG ZRUN RI DQG FKDOOHQJHV WR 1HZ =HDODQG·V
Pharmaceutical Management Agency (2014: 140-147) is also pertinent in this regard. 
PHARMAC, they accentuate, ZDVFUHDWHGGXULQJ´HIIRUWV«WRJURXQGKHDOWKVHFWRUUHIRUPVLQD
QHROLEHUDO LGHRORJ\µ, DOWKRXJK LWV ´DFWLYLWLHV LQWHUIHUH ZLWK YDOXHV SUL]HG E\ VXSSRUWHUV RI
QHROLEHUDOLVP«µ7KH$JHQF\·VFUHDWLRQLVVHHQLQFRQQHFWLRQZLWKWHQVLRQVEHWZHHQ
demands on the state (2014: 148). Moreira mentions that several sociologists have, in different 
ways, examined ´KHDOWK FDUH UHIRUPVµ RI UHFHQW GHFDGHV VSHFLILFDOO\ DV UHIRUPV ´LQ WKH QHR-
OLEHUDOHUDµELQGLFDWLQJthe importance of the question of neoliberalism to sociological 
discussions of healthcare generally. The following inquiry into KRZ1,&(·VDSSUDLVDODSSURDFK
shapes social relations is entwined with a detailed discussion of the consonances and dissonances 
between this approach and neoliberal thinking. It thus yields a further nuanced response to that 
question. 
$PRQJ WKH PRVW PXOWLIDFHWHG VRFLRORJLFDO VWXGLHV RI 1,&( DSSUDLVDO DUH 0RUHLUD·V
inquiries from an STS perspective. Moreira (2016) has investigated the confrontations over 
1,&(·Vdisapproval of NHS funding for dementia drugs. He traces cliniciaQV·FULWLFLVPVRI
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WKHXQFHUWDLQWLHVDQGWKHSROLWLFDOSUHVXSSRVLWLRQVLQ1,&(·VHFRQRPLFDVVHVVPHQWV-7, 
88-DVZHOODV1,&(·VSURGXFWLRQRIQHZHFRQRPLFHYDOXDWLRQVDQGDGYLFH-3). 
In VXEVHTXHQW GLVFXVVLRQV FOLQLFLDQV VKRZHG WKHLU SUHIHUHQFH IRU ´PHFKDQLFDO«REMHFWLYLW\µ, 
1,&( LWV SUR[LPLW\ WR ´UHJXODWRU\ REMHFWLYLW\µ  . In a closely related paper, Moreira 
(2012a) provides an intricate, far-reaching analysis of cases and human interest stories in further 
instances of oppoVLWLRQWR1,&(·VGUDIWJXLGDQFH Finally, Moreira demonstrates that the Appeal 
+HDULQJV FRQFHUQLQJ 1,&(·V  UHFRPPHQGDWLRQ RQ GHPHQWLD GUXJV FRQVWLWXWHG D decisive 
moment in the controversy (2011: 1336-1337). He elucidates this with reference to the appeals 
SURFHGXUH·V SDUWLFXODU ´LQVWLWXWLRQDO IRUPDWµ DQG E\ GUDZLQJ DWWHQWLRQ WR WKH ZD\ LQ ZKLFK
´NQRZOHGJH FODLPVµ ZHUH FRQQHFWHG ZLWK ´FRQFHSWLRQV RI MXVWLFH DQG IDLUQHVVµ  -
1338). But in the mid-2000s developed also another controversy over NICE·V appraisals, an 
LQWHUGLVFLSOLQDU\GHEDWHRQWKHHWKLFVRILWVDFWLYLWLHVQDPHO\LQZKLFKPRUHRYHU1,&(·V
statements on dementia drugs were once again addressed. Whilst this dispute has not yet 
undergone sustained sociological scrutiny, analysing it closely is indispensable to the following 
inquiry into the politics of NICE appraisal, especially regarding the cultivation of social relations. 
Lastly, sociologists have interrogated the QALY method central to health technology 
assessment. Moreira (2012b) and Wahlberg and Rose (2015), for instance, offer different 
perspectives on the QALY·s history. More significant for the present explorations, though, is 
6M|JUHQ DQG +HOJHVVRQ·V LQYHstigation of the work of the Swedish Pharmaceutical Benefits 
Board. They highlight, among other issues, the part health economic instruments play in 
´HFRQRPL]LQJ KHDOWK FDUHµ. $ IRFDO SRLQW RI WKHLU GLVFXVVLRQ LV WKH DSSOLFDWLRQ RI ´FDOFXODWLYH
WRROVDQGPHWULFVµIRU´FRPSDULVRQVµEHWZHHQGUXJVUHJDUGLQJ´FRVW-HIIHFWLYHQHVVµ
FRUPXODWLQJ´HIIHFWLYHQHVVµZLWKRQHVLQJOH´PHWULFµ HQDEOHVDQDO\VHVRIWKLVNLQGWR´FRPSDr[e] 
treatments of GLIIHUHQW LOOQHVVHVµ (2007: 219, emphases added). The QALY devised by health 
HFRQRPLVWV LV VXFK D ´PHWULFµ ,W UHYROYHV DURXQG FRQFHSWXDOLVLQJ ´HIIHFWLYHQHVVµ DV
´quantity«DQGquality RIOLIHµ6M|JUHQDQG+HOJHVVRQDVFULEH´DXQLYHUVDOYRFDWLRQµWR4$/<s. 
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7KH 4$/< ´proposes a criterion that permits«comparison between the most diverse 
WKHUDSHXWLF DOWHUQDWLYHVµ &RPSDULVRQV RI ´FRVW SHU 4$/<µ SURPRWH D UHODWLYHO\ ´DGYDQFHG
HFRQRPL]DWLRQµ RI KHDOWKFDUH  . QALY-based analyses, Arnesen and Norheim also 
mention, aim ´WRFRPSDUHWKHFRVWVDQG«EHQHILWVRIDOWHUQDWLYHKHDOWKSURJUDPPHVµ: ´DOONLQGV
RIKHDOWKJDLQVµDUHWREHUHQGHUHG´FRPSDUDEOHRQDQXPHULFOHYHOµ7KH\HPSKDVLVHWKDWXVLQJ
´DFRPPRQ¶FXUUHQF\·µHJWKH4$/<´IRUDOOKHDOWKRXWFRPHVµEHDUVERWKWKH´SRWHQWLDOµDQG
WKH´FRQWURYHUV\µRIWKLVW\SHRIDQDO\VLV Incidentally, )DXONQHUDQG0DKDODWFKLP\·V
study of debates on valuation and reimbursement regarding regenerative medicine in the UK 
GHVFULEHVUHFHQWFKDOOHQJHVWRWKH4$/<DV´DQHSLVWHPLFYDOXDWLRQWHFKQRORJ\µ230) and 
´WKH SRWHQWLDO XVH RI DOWHUQDWLYH YDOXDWLRQ SDWKZD\Vµ 1RQHWKHOHVV, DQG ´LWV KLVWRU\ RI
FRQWURYHUV\µ WRR, notwithstanding, WKH 4$/< LV SURYLQJ VRPHZKDW ´UHVLOLHQWµ  242). 
Crucially, the aforementioned dispute about NICE indicates that in appraisal the £/QALY 
comparison of health technologies is closely interlinked with the problem of competition. The 
second element has received much less attention in sociological discussions in this context, but 
FODULI\LQJERWKHOHPHQWVLVHVVHQWLDOIRUSURFHHGLQJWRGLVFXVVWKHSROLWLFVRIWKH,QVWLWXWH·VZRUN 
 
Approaching NICE 
For this purpose, two sets of documents have been analysed1,&(·VZHEVLWH G
especially its Guide to the Methods of Technology Appraisal (2013), details its approach to making 
recommendations for allocating NHS resources. The social value judgements statement (2008), 
the equality objectives (2016), and work by 1,&(·V Citizens Council (2019a) also illuminate 
UHOHYDQWGLPHQVLRQV1,&(·VFKDUWHUDQGIXUWKHUZHEVLWHPDWHULDOEFH
convey the wider context in which appraisal takes plDFH%XWRIFRXUVH1,&(·VSXEOLFDWLRQVGR
not contain everything there is to say about its activities. The second set makes this apparent.  
In the middle of the last GHFDGH 1,&(·V ZRUN EHFDPH WKH WRSLF RI D ORQJ, complex 
debate in the Journal of Medical Ethics. This fiery exchange was unusual in that it was conducted 
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across the widely bemoaned boundaries of academic disciplines and across the almost universally 
anathemised boundaries of university research. It involved a philosopher, John Harris (2005a, 
2005b, 2006, 2007), supported by ethicist and former medic Mureann Quigley (2007), and, on 
the other side, people variously linked to NICE, notably health economists Karl Claxton and 
Anthony Culyer (2006, 2007, 2008) as well as, initially, Rawlins and NI&(·V Chief Executive 
Andrew Dillon (2005). 
A vital dimension of this debate was the dLVSXWDQWV·GLVDJUHHPHQWabout evaluation and 
worth. ,Q  +DUULV FDVWLJDWHG 1,&(·V GHSOR\PHQW RI 4$/<V LQ LWV already mentioned 
provisional recommendation that dementia drugs not be NHS funded, which would, he stressed, 
HQWDLOGHQ\LQJ´WKRXVDQGVRI$O]KHLPHU·VSDWLHQWV«WKHRQO\WUHDWPHQWDYDLODEOHµ Based on the 
finding that tKH GUXJV· FRVWV H[FHHGHG ´¶«WKH UDQJH RI FRVW HIIHFWLYHQHVV WKDW PLJKW EH
considered appropriate IRUWKH1+6·µ1,&(·V recommendation, charged Harris, contained the 
´FRQGHPQ>DWLRQ@µ RI ´WKH SDWLHQWV«DV«QRW FRVW HIIHFWLYH WR WUHDWµ This implied the 
GHWHUPLQDWLRQWKDWWKHVHSHRSOHZHUH´QRWZRUWKKHOSLQJµD373, see also 2005b: 685). The 
Institute, he argued, VKRXOG UHIUDLQ IURP ´HYDOXDWLQJ SDWLHQWV UDWKHU WKDQ WUHDWPHQWVµ D
375). ,QUHSO\&OD[WRQDQG&XO\HUDFNQRZOHGJHGWKHGLVWLQFWLRQEHWZHHQVD\LQJ´¶WKHGUXJVDUH
QRWZRUWKLW·µDQGVD\LQJ´¶WKHSDWLHQWVDUHQRWZRUWKLW·µ<HW´WKHPHWKRGVRIFRVW-effectiveness 
DQDO\VLVµ WKH\ LQVLVWHG ´GR QRW HYDOXDWH SDWLHQWV QRU DVVHVV WKHLU ZRUWK«
EXW«¶SURFHGXUHV·«µVHHDOVR4XLJOH\, 2007: 465-466). 
4XLJOH\GHIHQGHG+DUULV·VDFFXVDWLRQWKDWWKH,QVWLWXWHZDV´¶«HYDOXDWLQJpatients rather 
WKDQ WUHDWPHQWV·µ 7KH ´FDPSµ VKH EHORQJHG WR HPSKDVLVHG 4XLJOH\ KHOG WKDW HPSOR\LQJ
4$/<VLQFKRLFHVEHWZHHQ´different treatments for different SDWLHQWVµLQYROYHG´YDOXHMXGJHPHQWV
DERXWSHRSOH·V OLYHVµ5HVROYLQJE\PHDQVRI4$/<VZKether to treat one patient or another 
HQWDLOVVKHQRWHG´EDODQFLQJWKHLPSURYHPHQW«LQWKHTXDOLW\RI>WKHIRUPHU·V@ OLIHµWLPHVWKH
´OLIH-\HDUV>WKHIRUPHU@JDLQV«DJDLQVWWKHVDPHFDOFXODWLRQIRU>WKHODWWHU@µ7KHKLJKHU´VFRUHµ
GHFLGHV ZKR LV PRUH ´FRVW HIIHFWLYH WR WUHDW IURP«OLPLWHG UHVRXUFHVµ 6XFK FRPSXWDWLRQV
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4XLJOH\ UHPRQVWUDWHG DPRXQW WR ´YDOXH MXGJHPHQWV DERXW WKH NLQG RI SHRSOH ZKR KDYH
ZRUWKZKLOH OLYHVµIn response, Claxton and Culyer again negated that the Institute 
H[DPLQHG ´WKH ¶ZRUWK· RI SHRSOH UDWKHU WKDQ WKH HIIHFWLYHQHVV RI WHFKQRORJLHVµ. NICE, they 
asserted, considers ´DOOLQGLYLGXDOVµ² VHYHUHO\LOOSHUIHFWO\KHDOWK\´\RXQJµ´ROGµHWF² RI´WKH
VDPH LQKHUHQW ZRUWKµ It does not UHFRPPHQG WHFKQRORJLHV ´DFFRUGLQJ WR SHRSOH·V ¶ZRUWK·
ZKHWKHU ¶ZRUWK· EH WKHLU FXUUHQW KHDOWK«SDVW KHDOWK«PRUDO GHVHUYLQJQHVV«ZHDOWK
RU«SURGXFWLYLW\µ-599). 
This issue of evaluation and worth alone is not decisive for the following discussion. 
However, it is entangled with two further ² pivotal ² matters: the disputants also address the 
FRPSDULVRQV FHQWUDO WR 1,&(·V DSSURDFK DQG, more explicitly than WKH ,QVWLWXWH·s own 
publications, raise the problem of competition. Informed by their contentions in addition to 
1,&(·VGRFXPHQWV, the next section highlights these two matters and casts them into sharper 
relief. That said, the contributions to the debate on NICE contain some inexact formulations. 
7RJHWKHU ZLWK WKH DQDO\VLV RI 1,&(·V RZQ VWDWHPHQWV UHJDUGLQJ LWV DSSUDLVDO DSSURDFK the 
analysis of the debate thus simultaneously supports the attempt, in the subsequent section, to 
offer a more precise characterisation not just of the comparisons in appraisal but also of the 
competition associated with them. In other words, on the basis of those analyses further 
perspectives are also brought to that debate. 
The inquiry into WKHSROLWLFVRI1,&(·VZRUN proceeds from this characterisation. First, a 
comparison between 1,&(·VDSSURDFKand efforts to foster competition often associated with 
neoliberalism is conducted. Foucault (2010), scholars drawing on his work, and, more recently, 
Davies (2014) have detailed this domain of neoliberal politics. This is followed by a comparison 
between 1,&(·V DSSURDFK and SiPPHO·V DQG :HEHU·V influential conceptions of social 
relationships, which focus on reciprocity and action respectively. N,&(·VRZQZD\RI VKDSLQJ
social relations and of creating positions for people through technology appraisal is thus 
illuminated. 
10 
 
 
 Comparison and competition 
 1,&(·VSURFHGXUH IRU PDNLQJ UHFRPPHQGDWLRQV DERXWZKHWKHU VFDUFH1+6 UHVRXUFHV
should be spent on new treatments is comparative (Claxton and Culyer, 2006: 373-376; Harris, 
2005a: 373; Quigley, 2007: 465; Rawlins and Dillon, 2005: 683). Contentiously among the 
disputants, 1,&(·V DLPRI ´VHUYLQJ WKHZKROHRI VRFLHW\µ requires it not only to ascertain the 
additional health for the particular patient group from, and extra cost of, a new technology. 
NICE must also consider the QALY yield for other patient groups in the NHS from other 
interventions that need to be discontinued to free up funds for the new technology. The 
´UDWLRQDOHRIFRVW-HIIHFWLYHQHVVDQDO\VLVµWXUQVRQFRPSDULQJ´KHDOWKJDLQHGDQGKHDOWKIRUJRQHµ
(Claxton and Culyer, 2006: 373-374)1. 7KH ´KHDOWKµ WKDW PXVW EH ´IRUJRQHµ ² because the 
LQWHUYHQWLRQVSURYLGLQJLWWR´RWKHUSDWLHQWVµPXVWEHJLYHQXp for funding the new technology ² 
LVGHFLVLYH LWGHWHUPLQHV LI´WKHFRVWSHU4$/<JDLQHGµE\ resourcing WKHQHZWHFKQRORJ\´is 
ZRUWKZKLOHµ &OD[WRQ DQG&XO\HU  -376). 7KH H[WUD ´KHDOWKEHQHILWVµ D patient group 
UHFHLYHVIURPDQHZGUXJIRULQVWDQFHPD\EHVPDOOHUWKDQWKHKHDOWKEHQHILW´RWKHUSDWLHQWVµ
PXVWVDFULILFHDV´RWKHUSURFHGXUHVµKDYHWRbe abandoned to pay for that new drug. The latter 
LV WKHQ´¶«QRWZRUWK LW·µ LHFRVW-ineffective (Claxton and Culyer, 2006: 373; see also Harris, 
2006: 378-379, 2007: 467; NICE, 2013: 10, 63-67). 
Crucially, these comparisons central to NICE guidance development have been 
associated with a competition. Whilst the term competition LV VFDUFHO\ XVHG LQ WKH ,QVWLWXWH·V
GRFXPHQWV DERXW DSSUDLVDO 1,&(·V appraisal methods guide explicitly addresses the issue of 
´costs DQG4$/<VIURP«FRPSHWLQJKHDOWKFDUHSURJUDPPHVµ13: 66). In a contribution to 
WKHGHEDWHRQ1,&(&OD[WRQ DQG&XO\HU UHIHU WRD ´FRPSHWLWLRQ«EHWZHHQ LQWHUYHQWLRQV«µ
DGGLQJ´VXFFHVVLQLWGHSHQGVRQZKDWWKHLQWHUYHQWLRQVFDQGRIRUSHRSOH·VKHDOWK«µ A new 
WHFKQRORJ\PD\EHVHHQ WRRIIHU´OLWWOHKHDOWKJDLQµ WR LWVSDWLHQWVEXWat great ´H[SHQVHµDQG
WKHVHIXQGVPD\EH´MXGJHGWRKDYHDKLJKHU\LHOGµIRUDQRWKHUJURXSZKHQLQYHVWHGLQDQRWKHU
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WUHDWPHQW7KDW WHFKQRORJ\ZLOO WKHQ´RWKHUFRQVLGHUDWLRQVµDVLGHSUREDEO\EHGHHPHG´FRVW-
LQHIIHFWLYHµ 8: 599)2. The comparison informing NICE appraisal, it is suggested, is also a 
competition, namely in generating QALYs/£, between two technologies for two groups with 
GLIIHUHQWFRQGLWLRQV7KHQHZWHFKQRORJ\IRUWKHRQHJURXSFRXOGHPHUJHDV´¶«QRWZRUWKLW·µ
DV ´¶QRW FRVW-HIIHFWLYH·µ DV&OD[WRQ DQG&XO\HU  -374) put it, as defeated. This helps 
NICE decide which procedures should be offered (Claxon and Culyer, 2008: 600). In drawing 
comparisons, NICE, one might say, arranges a competition between different interventions for 
different patients in the production of QALYs/£ ² in which some succeed, and others are 
defeated ² for scarce NHS resources. 
Upon closer inspection, though, the dispute about NICE reveals disagreement about this 
competition. The disputantV· disagreement is consistent with their aforementioned differences 
regarding the issue of worth, with which that of competition is intertwined. In full, Claxon and 
&XO\HU·VDVVHUWLRQMXVWFLWHGUHDGV´7KHFRPSHWLWLRQLVEHWZHHQinterventions, not people, and success 
LQ LW GHSHQGV RQ ZKDW WKH LQWHUYHQWLRQV FDQ GR IRU SHRSOH·V KHDOWK LUUHVSHFWLYH RI >SHRSOH·V@
¶ZRUWK·µ   HPSKDVHV DGGHG +DUULV E\ FRQWUDVW VSHDNV RI ´FRPSHWLWRUV IRU
WUHDWPHQWµ VXJJHVWLQJ WKH FRPSHWLWLRQ LV EHWZHHQ SHRSOH D  4XLJOH\ VLPLODUO\
mentions ´SDWLHQWVFRPSHWLQJIRUKHDOWKFDUHUHVRXUFHVµ 
 
Comparison and competition: treatments and patients 
TKLVSDUWRI1,&(·VZRUNcan be characterised more precisely. Clarifying the evaluation 
of health WHFKQRORJLHV&OD[WRQDQG&XO\HUXQGHUOLQHWKDWWHFKQRORJLHVDUHIRUWUHDWLQJ´SDWLHQWV
ZLWK SDUWLFXODU LQGLFDWLRQV DQG FKDUDFWHULVWLFVµ $ PHGLFDWLRQ IRU LQVWDQFH ´PD\ EH VDIH DQG
HIIHFWLYH IRU RQH JURXS«EXW«LQHIIHFWLYH RU«GDQJHURXV IRU DQRWKHUµ 6R WHFhnologies are 
OLFHQVHG ´IRU XVH RQ SDUWLFXODU SDWLHQWVµ EXW ´QRW IRU RWKHUVµ. They ´FDQ EH HYDOXDWHG RQO\
ZKHQ«XVHG IRU SDUWLFXODU SDWLHQWVµ  -375, see also 2008: 598). An DSSUDLVDO·V
assessment phase, states NICE, involves ´DVVHVV[ing] a technoloJ\·V FOLQLFDO DQG FRVW
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HIIHFWLYHQHVVIRUDVSHFLILFLQGLFDWLRQ«µVHHDOVR3. Whenever NICE appraises a 
technology, it appraises it for patients with a particular indication or specific characteristics. 
Thus NICE, having to consider both thHWHFKQRORJ\XQGHULQVSHFWLRQDQG´DOWHUQDWLYHµ
purposes to which the funds could be allocated (Claxton and Culyer, 2006: 373-374), considers 
the cost-effectiveness ratios of different technologies used on the respective patient groups, each 
of which has particular attributes. Several contributions to the dispute thematise this element of 
1,&(·VZRUNDQGLQGLFDWHLWVLPSOLFDWLRQV 
Rawlins and Dillon report the finding that alendronate for the secondary treatment of 
osteoporosis scores roughly £33,000/QALY for patients aged 50 and £12,000/QALY for 
SDWLHQWV DJHG  7KH ´ULVN RI FRPSOLFDWLRQV RI RVWHRSRURVLVµ WKH\ H[SODLQ LV KLJKHU Ln the 
VHFRQGJURXSZKLFKWKHUHIRUHJDLQVPRUH+DUULVUHSOLHVWKDWWRWKH,QVWLWXWH·V4$-
LY ´¶«PHDVXUHRIKHDOWKJDLQ·µOLIHWLPHLVYLWDO$SURFHGXUHLV´PRUH¶HIIHFWLYH·µLILWGHOLYHUV
´PRUH OLIH \HDUVµ 6R 4$/<V ´¶SUHIHU· PRUH OLIHWLPHµ ZKosoever has it. Yet normally, 
emphasises Harris, the young receive more lifetime from being treated. When QALYs play a part 
´LQFKRRVLQJEHWZHHQSDWLHQWVµ WKH\DUH OLNHO\ WR LQIOXHQFHGHFLVLRQV LQ IDYRXURI´JUHDWHU OLIH
H[SHFWDQF\XVXDOO\«SRVVHVVHGE\ WKH\RXQJHUFDQGLGDWHVIRUWUHDWPHQWµE 
&OD[WRQDQG&XO\HUZDUQDJDLQVWSUHVXPLQJDSURFHGXUH´PRUHFRVW-effective for those 
ZLWK D ORQJHU OLIHµ /HVV OLIH H[SHFWDQF\ PHDQV D VKRUWHU GXUDWLRQ RI ´EHQHILWµ EXW DOVR RI
expenditure. Moreover, Claxton and Culyer present an example of two populations, one with a 
KLJKHU ´ULVN RI DQ HYHQW FDUU\LQJ VRPH ULVN RI GHDWKµ RQH ZLWK D ORZHU ULVN DQG KLJKHU ´OLIH
H[SHFWDQF\µ7KH\SURSRVHLPDJLQLQJDWUHDWPHQWRIDJLYHQFRVWZKLFKUHGXFHVH[FOXVLYHO\´WKH
UHODWLYH ULVNµRI WKDW HYHQW ´:LWK WKH VDPH UHODWLYH HIIHFWµ WKH\QRWH ´WKH ULVN UHGXFWLRQZLOO
normally be greater in high-ULVNSRSXODWLRQVµ7KLVZLOORIWHQHQWDLOPRUHDGGHGOLIHWLPHIRUWKHVH
populations, hence a better cost-effectiveness ratio, altKRXJK WKH\ PD\ KDYH OHVV ´OLIH
H[SHFWDQF\µ )LQDOO\&OD[WRQ DQG &XO\HU PHQWLRQ WKDW RIWHQWLPHV LW LV ´TXLWH GLIILFXOWµ ² they 
appear to mean costly ² ´WR DFKLHYH VLJQLILFDQW LPSURYHPHQWV LQ WKH KHDOWK RI SHRSOH ZLWK 
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DOUHDG\ JRRG KHDOWKµ 6R SURFHGXUHV IRU DOUHDG\ TXLWH KHDOWK\ JURXSV PLJKW KDYH SRRU ´FRVW-
HIIHFWLYHQHVVµ 
These examples illustrate a conception of different cost-effectiveness ratios as outcomes 
not just of different treatments, but of different treatments applied to particular patient groups. 
%RWK D WHFKQRORJ\·V GLVWLnct properties and the corresponding SDWLHQW JURXS·V SDUWLFXODU
attributHVVKDSHDWHFKQRORJ\·s QALYs/£ value. As mentioned, crucial WRWKH´UDWLRQDOHRIFRVW-
HIIHFWLYHQHVVDQDO\VLVµLVWKH´FRPSDULVRQµ between ´KHDOWKJDLQHGµ² thanks to funding a new 
technology for a patient group ² DQG´KHDOWKIRUJRQHµ² because another technology for another 
group would thereby need to be dropped (Claxton and Culyer, 2006: 373-374, see also 375-376). 
This comparison can now be specified. NICE compares different treatments applied to 
particular patient groups; it compares one procedure in the treatment of the relevant patients, 
who have their own specific attributes, with another such combination. They are compared in 
view of their cost-effectiveness ratios, the number of QALYs per unit of health expenditure they 
produce. Funding a new technology beneficial to the corresponding patients when used to treat 
them requires abandoning another technology that, applied to its own specific patient group, 
produces health for this group. The health for the latter group is thus lost. The lost QALYs 
determine if the benefit from resourcing the new technology for treating its patients is 
worthwhile. They determine whether the new technology used on its corresponding particular 
patients is cost-effective (see Claxton and Culyer, 2006: 373-376; Harris, 2007: 467). As Claxton 
DQG&XO\HU UHSRUW ´SDWLHQWVZLWK$O]KHLPHU·VGLVHDVH DUH SUREDEO\QRWFRVW HIIHFWLYH WR WUHDW 
with these drugs, because other patients would (probably) get greater benefits from the use of 
WKH UHVRXUFHV VSHQW«WR DFTXLUH WKH GUXJV WR WUHDW $O]KHLPHU·V GLVHDVHµ   VHH DOVR
Harris 2005a: 373; Quigley, 2007: 465).  
These considerations, to indicate this briefly, have implications that stretch beyond key 
formulations about evaluation and worth on both sides of the dispute about the ethics of 
1,&(·VDFWLYLWLHV&OD[WRQDQG&XO\HUDFFHSW WKDW´FRPSDULQJ WUHDWPHQWV IRUGLIIHUHQWSHRSOHµ
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UHTXLUHV ´YDOXH MXGJHPHQWVµ. NICE, they underscore, takes costs into account and counts 
´KDYLQJ PRUHµ RI ´¶KHDOWK· DQG ¶KHDOWK JDLQ·µ DV ´D JRRG WKLQJµ 0RUHRYHU ´LQWHUSHUVRQDO
FRPSDULVRQV RI WKH YDOXH RI KHDOWKµ DUH LQWULQVLF WR DVVHVVLQJ ERWh the consequences of 
SURFHGXUHV IRU FHUWDLQ JURXSV· KHDOWK DQG SUHFLVHO\ ´WKH RSSRUWXQLW\ FRVWµ ² qua 
´KHDOWK«IRUJRQeµ² ´of actions on other groupsµ (2008: 598). However, vis-à-vis such matters 
precision is vital. NICE&OD[WRQDQG&XO\HU·VFRQWULEXWLRQQRWHV´FRPSDUH>V@WKHZRUWKRI
DOWHUQDWLYHSURFHGXUHVµLQUHVSHFWRIWKHLUDSSOLFDWLRQ·V´FRQVHTXHQFHV«IRUSDWLHQWVµ7KLVPD\
EH YLHZHG DV ´HYDOXDWLQJ RQH JURXS·V DELOLW\ WR EHQHILWµ IURP WKH SURFHGXUHs· DSSOLFDWLon 
´FRPSDUHGZLWKWKDWRIDQRWKHUµ<HWWKH\QHJDWHWKDWLWFRQVWLWXWHV´HYDOXDWLQJWKHZRUWK«RI
GLIIHUHQWSDWLHQWVµ, see also 2008: 598-599). Harris, by contrast, charges NICE with 
MXGJLQJWKDWWKH´SDWLHQWV«DUHQRWZRUWKKHOSLQJµD3). Quigley, as indicated, associates 
the use of QALYs under discussion with ´DFFHSWLQJWKDW«SDWLHQWVZLWKDEHWWHUTXDOLW\RI OLIH
DQGZKROLYHORQJHUKDYHPRUHZRUWKZKLOHOLYHVµDQGwith ´YDOXHMXGJHPHQWVDERXWWKHNLQGRI
SHRSOH«ZRUWKWKHH[SHQGLWXUHRISXEOLFUHVRXUFHVµ (2007: 466). What can be interjected in reply 
to the assertions on both sides is this: NICE judges that the QALY (quality and quantity of life) 
gain for one patient group of one treatment applied to them ² and hence this combination ² is 
not worth as much as the financial support it requires, because financial help of that magnitude 
enables another treatment in another group to generate a greater gain of just such QALYs for 
this other group. 7KH ´PHWhods of cost-HIIHFWLYHQHVV DQDO\VLVµ Claxton and Culyer hold, 
´«HYDOXDWHWUHDWPHQWVµ´QRW«SDWLHQWVµ Harris (2005a: 375) and Quigley see NICE 
´¶HYDOXDWLQJSDWLHQWV UDWKHU WKDQ WUHDWPHQWV·µ  In fact, NICE each time evaluates a 
treatment with distinct properties specifically as it is applied to the relevant patient group with its 
particular attributes, namely in that it evaluates the QALYs/£ that combination offers this 
group.  
More importantly in this context 1,&( PHQWLRQLQJ ´FRPSHWLQJ KHDOWKFDUH
SURJUDPPHVµLWDSSHDUVWKDWLWVGUDZLQJFRPSDULVRQVEHWZHHQGLIIHUHQWWHFKQRORJLHV
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for different patient groups (see Quigley, 2007: 465) must be understood as arranging 
competition. Indeed, insofar as QALYs/£ ratios are considered results of different treatments 
used in the respectively relevant particular patient groups, the competition Claxton and Culyer 
identify within appraisal can be characterised more precisely. They describe a 
´FRPSHWLWLRQ«EHWZHHQ interventions, not peopleµ LQ ZKLFK ´VXFFHVV«GHSHQGV RQ ZKDW WKH
LQWHUYHQWLRQVFDQGRIRUSHRSOH·VKHDOWKµ What must be interjected here is that the 
competition of healthcare programmes unfolds between one procedure with distinct properties 
specifically as it is used on the relevant patient group with its own particular attributes and 
another such combination. Success hinges on the contribution of a combination to its patient 
JURXS·VKHDOWK It is a competition in generating health for expenditure between one intervention 
applied to a patient group with one specific condition and another applied to a patient group 
with another. From this competition, one intervention applied to its relevant group may emerge 
as cost-ineffective (see Claxton and Culyer, 2006: 373-374) or defeated. This aids NICE in 
developing funding recommendations. NICE seems, through comparison, to arrange a 
competition between different treatments used on the respectively relevant specific patient group 
in generating QALYs/£ for these patients ² whereby some combinations succeed, and others do 
not ² for limited NHS resources. From these considerations it is possible to proceed to a 
sociological inquiry into WKHSROLWLFVRI1,&(·VDSSUDLVDODFWLYLWLHV 
 
Competition and differentiation 
6LQFH DV WKH FRQWULEXWLRQV WR WKH GHEDWH UHYLVLWHG DERYH VXJJHVW 1,&(·V DSSURDFK WR
producing funding recommendations turns not just on comparison but also on competition, 
such an inquiry seems prima facie to promise a strDLJKWIRUZDUGRXWFRPH7KHQHROLEHUDO´SROLWLFDO
SURMHFWµ LQYROYHV YLHZLQJ ´FRPSHWLWLRQµ DV ´WKH EDVLV RI VRFLDO UHODWLRQVµ DQG HIIRUWV WR
´IRVWH>U@µWKHVHYHU\UHODWLRQVKLSV5HDGVHHDOVR'DYLHV, 2014: 76). And certainly, the 
,QVWLWXWH·VDSSURDch resembles in many respects the way relations between people are said to be 
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shaped in neoliberalism. However, a finer-JUDLQHG FRPSDULVRQ EHWZHHQ 1,&(·V PRGH RI
procedure and what sociologists have pinpointed as concerns of neoliberalism ultimately shows 
WKHSROLWLFVRI1,&(·VZRUNWREHPRUHFRPSOH[SHUKDSVPRUHSUREOHPDWLF 
The neoliberal concern with competition is the subject of a sizeable literature, in which 
)RXFDXOW·V  OHFWXUHVRQQHROLEHUDOLVPDUH IUHTXHQWO\ LQYRNHG ,W LVRIWHQHPSKDVLVHG that 
IURPQHROLEHUDOLVP·VVWDQGSRLQW´FRPSHWLWLRQµLVWKH´HVVHQFHRIWKHPDUNHWµ*XGPDQG-Høyer 
and Lopdrup Hjorth, 2009: 118; see also Davies, 2014: 48). Neoliberalism proposes as a political 
objective that markets be established and cultivated. Opposing interventions in markets, it 
encourages the creation and promotion of an environment that helps markets operate. In other 
words, neoliberalism encourages the establishment and cultivation of competition. The 
´QHFHVVDU\ SUHFRQGLWLRQV IRU WKH IORXULVKLQJ RI competitionµ DUH WR EH FUHDWHG DQG promoted 
(Gudmand-Høyer and Lopdrup Hjorth, 2009: 118, see also 126; Davies, 2014: 40-44, 75-77, 199; 
Foucault, 2010: 140; Hamann, 2009: 41-42; Read, 2009: 28). 7KH ´HDUO\ QHROLEHUDOVµ 'DYLHV
VSHFLILHV VDZ ´RSHQ GHFHQWUDOL]HG PDUNHWVµ EXWWUHVVHG E\ WKH ´UXOH RI ODZµ DV WKH RSWLPDO
PHDQVRIHQVXULQJD´FRPSHWLWLYHVRFLHW\µ0HDQZKLOHWKRXJKLWKDVEHHQDVNHGLI´non-market 
LQVWLWXWLRQVSROLFLHVDQGLQWHUYHQWLRQVµFDQDOVREULQJWKHDGYDQWDJHVRI´FRPSHWLWLYHSUDFWLFHVµ
(2014: 43-44). 
Referring to DavieVDPRQJRWKHUV0HKUSRX\DDQG6DPLRORH[DPLQH´UHJXODWRU\
FDSLWDOLVPµ DV WKH FRQWH[W RI WKH ´UH-UHJXODWLRQ RI«VRFLHWLHV WKURXJK PDUNHWVµ 5HJXODWLRQ RI
this kind, they argue, VRPHWLPHV UHYROYHV DURXQG ´PRELOL]LQJ IRXQGDWLRQDO PDUNHW SURFHVVHV
such aVFRPSHWLWLRQDQGEHQFKPDUNLQJWRPRYHRUJDQL]DWLRQVµWRZDUGVD´«FROOHFWLYHJRDOµ$
FHQWUDO WRSLF RI WKHLU LQYHVWLJDWLRQ LV WKH RSHUDWLRQ RI ´SHUIRUPDQFH PHWULFV DQG UDQNLQJµ LQ
HQGHDYRXUV ´WR UHJXODWH LVVXHV FRQVLGHUHG RI SXEOLF LQWHUHVWµ WKURXJK ´FRPSHtition and 
EHQFKPDUNLQJµ 0HKUSRX\DDQG6DPLROR IRFus on the Access to Medicine Index, a 
UDQNLQJRISKDUPDFHXWLFDOFRPSDQLHVPHDQWWRDFWLYDWH´>P@DUNHW-PDNLQJDQGFRPSHWLWLRQµIRU
WKH SXUSRVH RI ´UHJXODW>LQJ@«KHDOWKµ   VHH DOVR 13, 25-28). They scrutinise 
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´FRPPHQVXUDWLRQµ DV D SUHUHTXLVLWH RI ´UDQNLQJµ   VHH DOVR -25), highlighting, inter 
alia WKH´FRPSDUDWLYHµGLPHQVLRQDVZHOODV WKH LPSRUWDQFHRIHVWDEOLVKLQJ´WKH ¶YDULDELOLW\·RI
FRPSDQLHV·SHUIRUPDQFHµDQGRIHQVXULQJ´GLIIHUHQWLDWLRQµEHWZHHQWKHP-24, see also 
13, 26-28). 
Discussing the Swedish Pharmaceutical Benefits Board, Sjögren and Helgesson, as 
mentioned, accentuate that computing QALYs supports costs/QALY comparisons between a 
wide variety of health interventions ² including between different interventions for different 
illnesses (2007: 219-220; see also Arnesen and Norheim, 2003: 81). Of note here, Sjögren and 
Helgesson seek to investigate how certain ² HVSHFLDOO\ HFRQRPLVWV· ² devices facilitate 
´FRQILJXULQJHOHPHQWVRIPDUNHWVµVHHDOVR0RUHRYHUWKH\PHQWLRQWKDWLQWKH
VSHFLILFVHWWLQJWKH\KDYHH[SORUHG´HFRQRPL]DWLRQ«DOVRPHDQWUHIOHFWLQJRQ«WKHLPSRUWDQFH
RI PDLQWDLQLQJ FRPSHWLWLRQ DPRQJ ILUPVµ DQG HVWDEOLVKLQJ ´WKH FRVWV Dnd advantages of 
GLYHUVLW\µEHIRUHSURFHHGLQJWRLOOXVWUDWHEULHIO\KRZWKHVHSUREOHPVZHUHDGGUHVVHG
in that setting (2007: 230-231). 
The problem of competition has also crystallised in connection with the comparisons 
central to NICE appraisal, albeit in a distinct way, too, and with implications worth spelling out 
in detail. NICE similarly assesses different procedures for patients with different conditions 
regarding how many QALYs per amount of expenditure they yield. NICE then compares the 
extra QALYs a new treatment would give its particular patient group with the QALY benefit 
´RWKHUSDWLHQWVµZRXOGKDYHWRVDFULILFHEHFDXVHRWKHUWUHDtments would need to be relinquished 
to buy the new one (Claxton and Culyer, 2006: 373-374). The comparison can be described as 
one between the £/QALY ratio of a procedure with distinct properties used on the 
corresponding patient group with its own particular attributes and the £/QALY ratio of another 
VXFK FRPELQDWLRQ ,Q 1,&(·V ZRUN LW KDV EHHQ VDLG PDNLQJ these comparisons of health 
technologies means arranging precisely a competition ² thus a competition between different 
procedures applied to the respectively relevant particular patient group in the generation of 
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QALYs/£ for these patients. It is in this VHQVHWKDW1,&(·VPRGXVRSHUDQGLUHVHPEOHVSROLWLFDO
objectives neoliberalism is held to support.  
,QIDFWLWVLPXOWDQHRXVO\GRHVVRLQDQDUURZHUVHQVH,Q´DQRUJDQL]HGFRPSHWLWLRQ«µ
'DYLHVKLJKOLJKWV´FRQWHVWDQWVµDUH´IRUPDOO\HTXDOµin the beginning but ´HPSLULFDOO\XQHTXDOµ at the 
HQG$WZRIROGGHPDQGRQHYHU\FRPSHWLWLRQLVVRPH´IRUPDOHTXDOLW\JXDUDQWHHGDWLWVRXWVHWµ
DQG VRPH ´FRQWLQJHQW LQHTXDOLW\«SURGXFHG DV LWV RXWFRPHµ  -42, see also 37, 199; 
Mehrpouya and Samiolo, 2016: 23- 1HROLEHUDOV KDYH D ´QRUPDWLYHµ QRWLRQ DFFRUGLQJ WR
ZKLFK´LQHTXDOLW\µ VKRXOG ´EH DFWLYHO\ JHQHUDWHGµ 'DYLHV  1RWDEO\ ´WKHQHROLEHUDO
promise of competitive forms of organization is that they will periodically produce clearly 
distLQJXLVKDEOH¶ZLQQHUV·DQG¶ORVHUV·«µ-57).  
)URP1,&(·VYLHZSRLQWWRVSHDNZLWK&OD[WRQDQG&XO\HUagain, every person, whatever 
WKHLU FXUUHQW KHDOWK DJH HWF KDV HTXDO ´LQKHUHQW ZRUWKµ  8). They underscore the 
´FRQVHTXHQWLDOLVWµ RULHQWDWLRQ RI WKH ,QVWLWXWH·V DSSURDFK LW GHHPV LPSRUWDQW ´FKDQJHV LQ
>VRPHRQH·VKHDOWK@«DWWULEXWDEOH WR D WHFKQRORJ\µ   DSSOLHG WR WKDWSHUVRQ. But one 
4$/< LV JHQHUDOO\ MXGJHG WR EH ´RI HTXDO VRFLDO YDOXHµ QR PDWWHU ZKR JHWV LW &OD[WRQ DQG
Culyer, 2006: 376; see also NICE, 2013: 40-41; Shah et al., 2013). 
In turn, the competition in producing QALYs/£ arranged at the core of NICE appraisal 
is meant WR´GLIIHUHQWLDWHµ WRUHQGHU´XQHTXDOµ WRVSHDNZLWK0HKUSRX\DDQG6DPLROR 
24) and Davies (2014: 41, italics removed) respectively. From it, some treatments in their 
corresponding particular patients emerge as cost-effective, as successful, others in their patients 
as cost-LQHIIHFWLYHDVXQVXFFHVVIXO7KURXJKWKHFRPSDULVRQLQ1,&(·VZRUN´VRPH PD\«JDLQ
DQGVRPHPD\«ORVHµDV&OD[WRQDQG&XO\HUSXWLW$GGLWLRQDOFRQVLGHUDWLRQVDVLGH
the winning combination receives NHS funding. For the patients within it, this means receiving 
extra health from being treated. The resonances with the neoliberal cultivation of competition 
are sustained.  
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Competing creatures 
$WWKHVDPHWLPH1,&(·VDSSUDLVDODSSURDFKGLYHUJHVIURPZKDWLVRIWHQFRQVLGHUHGD
YLWDO VWUDQG RI QHROLEHUDO WKLQNLQJ 7KH SROLWLFV RI WKH ,QVWLWXWH·V ZRUN WXUQV RXW WR EH PRUH
multifaceted and, arguably, problematic than it initially appears. In particular, it has been noted 
that neoliberal conceptions of competition tend to be intertwined with conceptions of the 
subjects competing with one another (e.g. Read, 2009: 27-´1HROLEHUDOLVP«LV«SURGXFHGE\
VWUDWHJLHV«DQGSROLFLHVWKDWFUHDWHVXEMHFWVRILQWHUHVWORFNHGLQFRPSHWLWLRQµ5HDG
see also 34-35). Reading Foucault (2010), Gudmand-Høyer and Lopdrup Hjorth mention that 
WKH´LGHDOL]HGILJXUHµRI*HUPDQRUGROLEHUDOLVPIRUH[DPSOHLVD´FRPSHWLWLYHDQGSURGXFWLYH
FUHDWXUH RI HQWHUSULVHµ &XOWLYDWLQJ WKH ´HQWHUSULVH IRUPµ LQYROYHV ´PRELOL]>LQJ@«D«VRFLDO
rWKRVµ ZKLFKGHOLPLWV D´FRPSHWLWLYHDQGHQWHUSULVLQJµPRGHRIFRQGXFW´LQ WHUPVRISHUVRQDO
plans and projects anG ZLWK«REMHFWLYHV WDFWLFV DQG DJHQGDVµ  -120, see also 126; 
Davies, 2014: 20-21, 75; Foucault, 2010: 241). US neoliberal thinkers similarly conceptualise 
´KRPR ±FRQRPLFXVµ DV WKH ´FUHDWXUH RI FRPSHWLWLRQµ HYHU\ SHUVRQ ´HPERGLHV«DVVHWV DQG
producWLYLW\µPDQDJHVWKHLU´FRQVXPSWLRQµJHQHUDWHVWKHLU´VDWLVIDFWLRQµDQGHDUQVWKHLU´RZQ
ZDJHVµ*XGPDQG-Høyer and Lopdrup Hjorth, 2009: 120-121; see also Hamann, 2009: 54; Read, 
2009: 27- 6SHFLILFDOO\ ZDJHV DUH SURGXFHG WKURXJK VSHQGLQJ ´¶KXPDQ FDSLWDO·µ RQH·V
´JHQHWLFTXDOLWLHVµDQGRQH·V´DFTXLUHGµDWWULEXWHV OLNHVNLOOVRUNQRZOHGJH+DPDQQ-
$FFRUGLQJ WR)RXFDXOW·V OHFWXUHVRQQHROLEHUDOLVPZKLFKIRUPDFRPPRQUHIHUHQFHSRLQW
here, too, US neoliberals demand that economics spotligKW ´WKH VWUDWHJLF SURJUDPPLQJ RI
LQGLYLGXDOV· DFWLYLW\µ WKH ´FDOFXODWLRQµ ZKHUHE\ VRPHERG\ GHFLGHV WR XWLOLVH WKHLU PHDQV IRU
particular purposes (2010: 223, see also 268-269; Davies, 2014: 85-86). As Hamann clarifies, 
neoliberal thinkers seek to unearth WKH´UHDVRQLQJµWKDWPDNHVDSHUVRQGHYRWHWKHLU´OLIH·VILQLWH
FDSDFLWLHVµWR´SXUVXLQJRQHJRDORUDJHQGDUDWKHUWKDQDQRWKHUµ:RUNHUVDQGZRUN
especially, are framed in these ways (Foucault, 2010: 223-226). 
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6XFK´FDOFXODWHGFRPSHWLWLYHDQG VWUDWHJLFµFRQGXFWDGGV'DYLHVFDQQRWEH WDNHQIRU
granted anymore (2014: 159, see also 152, 166- &RQFHSWLRQV RI WKH ´UDWLRQDO HFRQRPLF
DFWRUµDUHLQFUHDVLQJO\RSHUDWLQJDV´QRUPVµof conduct. The economic human being is now often 
´QXUWXUHGLQWRH[LVWHQFHµ3HRSOHDUHWKRXJKWWRUHTXLUHVXSSRUWLQUHFRJQLVLQJDQG´DFW>LQJ@LQWKHLU
RZQLQWHUHVWVµVHHDOVR-7KH\PXVW´EHWDXJKWDQGQXGJHGWRGHFLGH«LQD
certain utility-PD[LPL]LQJ ZD\µ   +DPDQQ SRLQWV RXW WKDW ´QHROLEHUal 
JRYHUQPHQWDOLW\µ VHHNV WR JHQHUDWH ´VRFLDO FRQGLWLRQVµ IDYRXUDEOH WR WKLV W\SH RI LQGLYLGXDO
(2009: 39, see also 58- $FFRUGLQJ WR 5HDG WKH ´VXEMHFWVµ RI QHROLEHUDOLVP UHTXLUH WKH
´IUHHGRPµWRVHOHFWDPRQJ´VWUDWHJLHVµ7KLVKXPDQEHLQJFRQFHLYHGRI as an economic being is, 
KHVSHFLILHVXQGHUVWRRGDV´DFUHDWXUHZKRVHWHQGHQF\WRFRPSHWHPXVWEHIRVWHUHGµ-
29). In Gudmand-+¡\HU DQG /RSGUXS +MRUWK·V WHUPV LQ QHROLEHUDOLVP LW LV ´WKH IUHHGRP RI
OLEHUDWHGFRPSHWLWLYHQHVVµWKDWLVVHHQDVGHPDQGLQJ´VHFXULW\µ 
These discussions illuminate an important dimension of the neoliberal idea of 
competition as a mode of differentiation and of generating distinct winners and losers (Davies, 
 1HROLEHUDO WKLQNLQJ LQYROYHV WKLQNLQJ HYHU\RQH ´¶HTXDOO\ XQHTXDO·µ DQG XQGHUVWDQGLQJ
HYHU\RQH·V´VRFLDOFRQGLWLRQµDVDUHVXOWRI´KLVRUKHURZQFKRLFHVDQGLQYHVWPHQWVµ+DPDQQ
 VHHDOVR'DYLHV)RXFDXOW´6RFLDOGLYLVLRQV«H[LVWµ WKDW LV\HW
´QHROLEHUDOLVP DWWULEXWHV WKRVH GLYLVLRQV WR IDLOXUHV RI individual choice and resSRQVLELOLW\µ
(Hamann, 2009: 50). Indeed, the discussions of neoliberal conceptions of subjects in competition 
indicate that competition is generally understood to unfold between agents with specific means, 
notably capacities, who decide to use these possibly following calculation, certainly following 
thought and strategising4. From this angle, the differentiation and distinction between winners 
and losers ensuing from competition would to a great extent be determined by a contest between 
subjects who make considered choices to act in their respective ways. The intricacies of the 
SROLWLFVRI1,&(·VZRUNVXUIDFHKHUH 
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Capturing such intricacies need not mean focusing on patients. NICE appraisal is a 
response to the problem of limited healthcare resources. Research on clinical effectiveness, the 
application of the QALY, the quantification of cost-effectiveness ² the ratio of which is deemed 
a result of different treatments offered by different manufacturers and applied to particular 
patient groups ² and comparison all contribute to the arrangement of competition. Technology 
appraisal thus presents many relevant focal points for sociological inquiry. Still, in this context 
highlightinJ WKH SDWLHQWV· VLWXDWLRQ is legitimate. 2QH RI WKH ´3ULQFLSOHV WKDW JXLGH WKH 1+6µ
DFFRUGLQJWRWKH6HUYLFH·VFRQVWLWXWLRQLVWKDWWKH´SDWLHQWZLOOEHDWWKHKHDUWRIHYHU\WKLQJWKH
1+6GRHVµ'HSDUWPHQWRI+HDOWK Yet certain formulations in defence of NICE in the 
debate explored HDUOLHUSRWHQWLDOO\REVFXUHSUHFLVHO\ WKHSDWLHQWV·UROH LQWKHFRPSHWLWLRQDWWKH
KHDUWRI1,&(DSSUDLVDO &OD[WRQDQG&XO\HU1,&(·VGRFXPHQWVGRQRWUHQGHU LW
particularly explicit either. This justifies the attempt ² HYRFDWLYHRIVRPHRI+DUULV·Va) and 
4XLJOH\·VIRUPXODWLRQV² WRVFUXWLQLVHWKHSDWLHQW·VSRVLWLRQFUHDWHGE\1,&(DSSUDLVDO. 
In appraisal, patient groups, by virtue of their specific properties, have a key part in their 
respective treatmHQWV·SURGXFWLRQRI4$/<s/£. Thus they are embroiled in the competition in 
generating QALYs/£. Crucially, though WKHVLWXDWLRQ1,&(·VDSSURDFKFRQVWUXFWVIRUSDWLHQWV
FRQWUDVWV VKDUSO\ ZLWK WKDW RI WKH ´FUHDWXUH RI FRPSHWLWLRQµ Gudmand-Høyer and Lopdrup 
Hjorth, 2009: 120) found to be conceptualised in neoliberalism. Notably, whilst the patient 
embodies factors influential on the generation of QALYs/£, the patient does not allocate or 
utilise those attributes for health production following her or his own considerations or 
calculations and strategic decision making. The extent of the production of QALYs/£ of each 
competitor depends RQ WKH SDWLHQW JURXS·V VSHFLILF DWWULEXWHV DV FRUUHVSRQGLQJ SDUWLFXODU
treatments are made to operate upon them, not as patients, reasoning, choose strategically to 
employ them. That is, whilst patients are involved in the competition in producing health/£, 
they never assume the position of subjects taking considered decisions to act in that contest. 
They are, perhaps, creatures of competition after all, more so, namely, than they are its agents, 
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notwithstanding that the competition can have major consequences precisely for patients. For it 
plays an important role in differentiating, with regards to £/QALY produced, between 
treatments used on their respectively relevant specific patient groups and in separating the cost-
effective from the cost-ineffective. This informs funding recommendations in the manner 
already specified. 
 
NICE and social relations 
It can also be shown ² albeit here necessarily only concisely ² KRZ1,&(·VZRUNVKDSHV
relationships between people in terms more general than those of competition. Comparing 
1,&(·V DSSURDFK ZLWK FRQFHSWLRQV RI WKH VRFLDO UHODWLRQVKLS WKDW KDYH EHHQ VHPLQDO LQ
sociological thought renders this apparent. 7KHYLHZWKDW1,&(·VZRUNIDFLOLWDWHVFHUWDLQVRFLDO
UHODWLRQVLVLQVWDQWO\IXUWKHUFRUURERUDWHGLQOLJKWRIDEDVLFHOHPHQWRI6LPPHO·VQRWLRQRIVRFLDO
relations. To Simmel, as is well known, studying social relations means stXG\LQJ ´UHFLSURFDO
HIIHFWµRU´LQWHUDFWLRQµ)ULVE\[LYVHHDOVR[[YL-52, 59-63, 1981: 40-44, 96; Simmel, 
1909: 292- ´6RFLHW\ LV FRPSRVHG RI WKH FHDVHOHVV LQWHUDFWLRQ RI LWV LQGLYLGXDO HOHPHQWV ² 
groups as well as individuals ² which impelV 6LPPHO·V VRFLRORJ\ WRZDUGV D FRQFHUQ IRU VRFLDO
relationships LH WRZDUGV WKH VWXG\ RI VRFLDO LQWHUDFWLRQµ )ULVE\   Humans, writes 
Simmel, ´LQIOXHQFH RQH DQRWKHU«WKH RQH GRHV RU VXIIHUV VRPHWKLQJ PDQLIHVWV D EHLQJ RU D
EHFRPLQJEHFDXVHRWKHUVDUHWKHUHDQGH[SUHVVWKHPVHOYHVDFWRUIHHO«µVHHDOVR
Frisby, 2002: 99). 1,&(·VDSSURDFKFDQEHVDLGWRVKDSHUHODWLRQVKLSVEHWZHHQpatient groups in 
the direction of reciprocal effects. For the number of QALYs per given amount of spending 
generated when a particular patient group is treated with a specific procedure is meant to 
influence whether the NHS ought to fund other interventions used in their respective other 
patients ² given their QALY/£ values ² for these other patients. And the QALYs/£ produced 
when other patient groups are treated with their respective interventions is supposed to be a 
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factor for whether the Service should resource a specific procedure used on a particular patient 
group ² given its QALY/£ value ² for this group. 
+RZHYHU6LPPHOFRQWLQXHVWKDWYDULRXV´LPSXOVHVµfor instance ´>H@URWLFµRU´UHOLJLRXVµ
RQHV DQG ´SXUSRVHVµ IRU LQVWDQFH ´RI GHIHQVHµ RU ´JDLQµ lead somebody to 
´H[HUFLVH«LQIOXHQFHXSRQµDQGEH´LQIOXHQFHGE\µRWKHUVVHHDOVR)ULVE\
52-54, 61-65, 2002: 51-52, 61- 0RUHRYHU DV )ULVE\ UHIHUULQJ WR 6LPPHO·V HVVD\ RQ WKH
SRVVLELOLW\ RI VRFLHW\ SKUDVHV LW 6LPPHO·V FRQFHSWLRQ RI VRFLDO OLIH SODFHV HPSKDVLV RQ ´WKH
FRPPLWPHQWRIHPSLULFDOVXEMHFWVWRLQWHUDFWLRQµVHHDOVR)URPWKLVDQJOH
´VRFLHW\SUHVXSSRVHV ¶FRQVFLRXVQHVVRIVRFLDWLQJRUEHLQJVRFLDWHG·µ)ULVE\[YLVHHDOVR
61, 121-123, 1981: 64-67). Bearing this in mind urges a specification of the qualities of the social 
UHODWLRQV1,&(·VZRUNLVKHOSLQJWRIRVWHU 
These qualities can, in actual fact, be sketched more sharply still by briefly comparing 
1,&(·VDSSURDFKZLWK:HEHU·VFRQFHSWRIWKHVRFLDOUHODWLRQVKLS$FFRUGLQJWR:HEHU´¶VRFLDO
UHODWLRQVKLS·µPHDQV´«EHKDYLRURI«DFWRUVLQVRIDUDV LQLWVPHDQLQJIXOFRQWHQWWKHDFWLRQRI
HDFK WDNHVDFFRXQWRI WKDWRI WKHRWKHUV DQG LVRULHQWHG LQ WKHVH WHUPVµ -27; see also 
Albrow, 1990: 159; Käsler, 1988: 154-155; Ringer, 1997: 158- ´7KH VRFLDO UHODWLRQVKLSµ
:HEHUXQGHUOLQHV´consists«H[FOXVLYHO\«LQWKHchance that actions have taken, are taking, or will 
take place which, in their meaning content, are«DGMXVWHG WR HDFK RWKHUµ (1980: 13, cited in 
English in Ringer, 1997: 159, whose translation, superior to Weber, 1978: 27, has been modified 
here; see also Albrow, 1990: 160-162; Käsler, 1988: 154-155). It is cultivating this kind of 
relationships between patients WKDW 1,&(·V DSSUoach is unconducive to ² notwithstanding its 
shaping SDWLHQWV· relations towards reciprocal effect. In particular, the production of QALYs/£ 
when a specific patient group receives a specific procedure influences whether the NHS should 
invest in other interventions used in their respective other patients. Yet the production of 
health/£ of that specific group when treated with its procedure is not in any dimension meant to 
EHRULHQWHGE\WKHSDWLHQWV·DGMXVWPHQWRIDQ\SDUWRIKHDOWKSURGXFWLRQLQLWVPHDQLQg content, 
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with regards to its impact on other patients in the NHS. This may be unsurprising thanks to the 
foregoing discussion. But the point is sociologically decisive: each patient group is here involved 
LQH[HUFLVLQJLQIOXHQFHRQRWKHUVZKLOVWWKHSDWLHQWV·DWWLWXGHWRZDUGVRUFRQVLGHUDWLRQRIRWKHU
people and the influence they potentially have on others are not supposed to give any direction to 
how that influence is exercised. Just like it fosters only a very specific form of competition, 
1,&(·V DSSURDFK IRVWHUV VRFLDO UHODWLRQV LQ D YHU\ SDUWLFXODU DQG restricted sense. During the 
GLVSXWHRQWKHHWKLFVRI1,&(·VDFWLYLWLHVIURPZKLFKWKLVH[SORUDWLRQVHWRXW+DUris accused the 
Institute of HPSOR\LQJD´PHWULFRIFRVW-HIIHFWLYHQHVVWKDWODFNVFRPSDVVLRQµDThe 
SROLWLFV RI 1,&(·V ZRUN GHVHUYHV VXVWDLQHG FULWLFDO DWWHQWLRQ IURP VRFLRORJLVWV E\ FRQWUDVW
because it supports the cultivation of social relations without spirit. 
 
Conclusion 
As noted at the outset, NICE explicitly thematises WHFKQRORJ\ DSSUDLVDOV· SRWHQWLDO WR
shape relationships between people, for instance by emphasising its ´commit[ment] 
WR«IRVWHULQJJRRG UHODWLRns, as required by the (TXDOLW\$FWµ . It is also worth 
reiWHUDWLQJ WKH 1,&( &LWL]HQV &RXQFLO·V IXQFWLRQ WR DGYLVH WKH ,QVWLWXWH ´RQ FKDOOHQJLQJ
VRFLDO«LVVXHVµ WKDW HPHUJH GXULQJ ´JXLGDQFHµ SURGXFWLRQ   Participants in the 
aforementioned 2014 session H[SUHVVO\FRQVLGHUHG´ZKDW>¶DJRRGVRFLHW\·@ZRXOGORRNOLNHµDQG
´FRQVLVWRIµ2014: 15). To orientate the SUHVHQWSDSHU·V discussions, it needed to be clarified that 
NICE, in making QALY/£ comparisons, arranges a competition which involves patient groups. 
This made it possible to specify and scrutinise the competition and the social relations more 
generally speaking that NICE appraisal helps foster. Given its attention to social issues, these 
would be highly pertinent topics for the &RXQFLO·VGHOLEHUDWLRQV. 1HLWKHU1,&(·VGRFXPHQWVQRU 
the mid-2000s dispute ² conducted chiefly in health economic and ethical terms ² have fully 
unlocked the issue of competition associated with 1,&(·V FRPSDULVRQV. However, the 
sociological conceptions that have guided the inquiry above could inform, extend, and enhance 
25 
 
the Council·V work. In this precise sense, the relevance of such inquiries transcends VRFLRORJ\·V
boundaries. Better supported in pursuing the problem of the good society, Council deliberations, 
in turn, could transcend those of the health system. 
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1 1,&( KDV GHILQHG D WKUHVKROG ´UDQJHµ RI -4$/< DQG LQVSHFWV WUHDWPHQWV XQGHU DSSUDLVDO ´LQ
UHODWLRQ WRµ LW  7Ke figure is controversial in the debate in focus here (Claxton and Culyer, 2006: 374, 
2007: 462; Harris, 2005a: 373, 2006: 378-379, 2007: 467) and elsewhere (see e.g. Appleby, 2016). 
2 RegardLQJDUHODWHGPDWWHU+DUULVPHQWLRQV´ULYDOWKHUDSLHVµD´2IRUUHODWLQJWRDUival; that is a rival 
RUULYDOVFRPSHWLQJµOxford English DictionaryVY´ULYDOµ&OD[RQDQG&XO\HUPHQWLRQ´ULYDOVµ-
376). 
3 The foregoing ´scopingµ SKDVHLQYROYHVVSHFLI\LQJ1,&(·V´¶TXHVWLRQ·µHJ´for which conditionµ DQG´in which 
patient (sub)groupµ a ´technology will be appraisedµ6RDUHV 
4 Though IRFXVHGRQTXLWHVSHFLILFPDWHULDOV'DYLHV·V-69) exploration of theories of competitive agency is 
worth mentioning in this context. 
